ONCAlert | 2017 San Antonio Breast Cancer Symposium

News

Ivosidenib Submitted for FDA Approval in IDH1+ AML
Ivosidenib Submitted for FDA Approval in IDH1+ AML
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.